ResearcherSarcoma Oncology CenterNo recent work listed
Sant P. Chawla
Matched on ORCID iD 0000-0002-9522-6744; OpenAlex author ID A5073906112. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 5
- Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and… Co-author DOI 10.3389/fmmed.2022.1092286↗
- Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with De… First author DOI 10.3892/mco.2021.2348↗
- Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse… Co-author DOI 10.1016/j.canlet.2020.07.034↗
- A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.omto.2018.12.005↗
- Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy. Co-author DOI 10.21873/anticanres.13726↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Erlinda Maria Gordon · 3 shared papers, 2019–2022 · strength 0.42
- Paper Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinom… DOI 10.3892/mco.2021.2348↗
- Paper Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancrea… DOI 10.3389/fmmed.2022.1092286↗
- Paper A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanc… DOI 10.1016/j.omto.2018.12.005↗
- Howard W. Bruckner · 2 shared papers, 2019–2021 · strength 0.27
- Paper Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinom… DOI 10.3892/mco.2021.2348↗
- Paper A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanc… DOI 10.1016/j.omto.2018.12.005↗
- Michael Andrew Morse · 2 shared papers, 2019–2021 · strength 0.27
- Paper Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinom… DOI 10.3892/mco.2021.2348↗
- Paper A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanc… DOI 10.1016/j.omto.2018.12.005↗
- Michael Bouvet · 2 shared papers, 2019–2020 · strength 0.18
- Paper Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with ag… DOI 10.1016/j.canlet.2020.07.034↗
- Paper Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Ch… DOI 10.21873/anticanres.13726↗
- Kentaro Miyake · 2 shared papers, 2019–2020 · strength 0.18
- Paper Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with ag… DOI 10.1016/j.canlet.2020.07.034↗
- Paper Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Ch… DOI 10.21873/anticanres.13726↗
- Norihiko Sugisawa · 2 shared papers, 2019–2020 · strength 0.18
- Paper Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with ag… DOI 10.1016/j.canlet.2020.07.034↗
- Paper Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Ch… DOI 10.21873/anticanres.13726↗
- Robert M. Hoffman · 2 shared papers, 2019–2020 · strength 0.18
- Paper Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with ag… DOI 10.1016/j.canlet.2020.07.034↗
- Paper Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Ch… DOI 10.21873/anticanres.13726↗
- Yuki Homma · 1 shared paper, 2020 · strength 0.09
- Hiroto Nishino · 1 shared paper, 2020 · strength 0.09
- Jun Yamamoto · 1 shared paper, 2020 · strength 0.09
- Itaru Endo · 1 shared paper, 2020 · strength 0.09
- Kei Kawaguchi · 1 shared paper, 2019 · strength 0.09
- Michiaki Unno · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.